NantOmics to Present Results of DESMOPAZ Study from French Sarcoma Group (FSG) at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

Results to be presented during the sarcoma session at the ASCO 2018 Annual Meeting
 

CHICAGO--(BUSINESS WIRE)-- NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present findings on how pazopanib (PZ) has meaningful clinical activity in patients with progressive desmoid tumors (DT) during the sarcoma session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event bringing together 30,000 oncology professionals from June 1-5, 2018 at McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at booth #7147 during the event.

“We’re thrilled to share safety and quality of life data on the benefits of pazopanib in patients with progressive desmoid tumors,” said Patrick Soon-Shiong, MD, founder of NantWorks. “No randomized trial assessing systemic treatment activity in this rare disease has been reported previously, so this data is a positive step forward for patients.”

Presentation Details

DESMOPAZ Pazopanib (PZ) versus IV Methotrexate/Vinblastine (MV) in adult patients with Progressive Desmoid Tumors (DT) a Randomized Phase 2 Study from the French Sarcoma Group (FSG), Abstract #11501
WHO: NantOmics, LLC
WHAT: Sarcoma Session
WHEN: June 4, 8:00-11:30 AM CST
WHERE: S100a, McCormick Place

Presentation Summary

To determine if PZ or IV methotrexate/vinblastine (MV) better treat desmoid tumors (DT), a DESMOPAZ from the French Sarcoma Group (FSG) was conducted. DESMOPAZ is a multicenter non-comparative randomized phase II trial based on a two-stage optimal Simon’s design assessing safety and efficacy of PZ in DT adult patients. All patients had to have documented progressive disease (PD) based on two imaging within a 6-months interval. Treatment was administered until PD (cross-over then permitted), unacceptable toxicity, and for a maximum of 1 year. The primary endpoint was 6-month non-PD rate according to RECIST 1.1. The results found that PZ has meaningful clinical activity in patients with progressive DT.

About NantOmics

NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular analysis capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular analysis company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumor sample used for genomic analysis. For more information please visit www.nantomics.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

 

Contacts

NANT
Jen Hodson
jhodson@nantworks.com
or
Henry Jackson, 310-486-8908
cj@nantworks.com

 

 
 

Source: NantOmics, LLC

Back to news